Bridging the Needs of Security and Development Teams, Veracode Unveils Next-Generation Software Security Platform
4.5.2022 15:12:00 EEST | Business Wire | Press release
Veracode, a leading global provider of application security testing (AST) solutions, today announced its Continuous Software Security Platform, which seamlessly embeds application security into the software development lifecycle (SDLC). The platform streamlines workflows by bringing together development and security teams to provide a broad understanding of risk, remediation guidance, and progress at every stage of the development process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005671/en/
Fig. 1 The Veracode Continuous Software Security Platform (Graphic: Business Wire)
According to Veracode’s latest research, there has been a 20x increase in average scan cadence over the past decade, with most applications tested three times per week, as opposed to three times per year a decade ago. The research also showed a 31 percent increase in organizations using multiple scan types over the last three years alone.
Today, leading organizations recognize the need to leverage multiple methods to assess their software and do so across all stages of the development lifecycle. Gartner® predicts that “by 2025, 70% of organizations will consolidate the number of vendors securing the lifecycle of cloud-native applications to a maximum of three vendors.” ¹ This suggests companies are already looking for a comprehensive platform that provides flexible policy management, a holistic assessment of software risk, and integrated remediation guidance, while simplifying the complexity of managing multiple solutions.
Pervasive but Not Invasive for Developers
With increased pressure to build and deploy software at breakneck speed, development teams require security checks to be seamlessly integrated into the tools where they work so they can find and fix vulnerabilities quickly. Meanwhile, security teams must meet increasingly stringent compliance standards defined by their boards and regulatory bodies. Veracode’s Continuous Software Security Platform is pervasive but not invasive because it provides a frictionless experience for developers by embedding vulnerability analysis with remediation guidance directly into the integrated development environment.
Brian Roche, Chief Product Officer at Veracode, said, “Other vendors in our space have incomplete or disjointed solutions that lack consistent reporting and analysis, leaving customers playing a game of ‘whack a mole’ across different tools. We have continued to evolve our platform to create a seamless and integrated experience for developers, as well as provide security teams with a holistic view of their software security posture from design, through development and deployment. We see this as a win for both development and security teams that will result in the delivery of software that is more secure.”
Veracode Continuous Software Security Platform
The Veracode Continuous Software Security Platform enables users to define and manage security policy, gain a comprehensive view of software security across their application portfolio, and leverage rich analytics to make informed plans, communicate metrics, comply with policy, and meet regulatory requirements. Powered by almost two decades of data, the platform enables organizations to detect, predict, manage, and, ultimately, mitigate their security risk. These intelligent capabilities empower companies to deliver secure code at the speed and scale expected in today’s world.
The new Veracode Continuous Software Security Platform release features several new capabilities including:
- Single-Pane-of-Glass Reporting: Security teams can now access unified reporting directly in the portal for Static Analysis, Dynamic Analysis, Software Composition Analysis, and Manual Penetration Testing. Administrators and developers now have a consolidated view into security risks, as well as flexible policy controls through stronger license management reports to address issues quickly.
- Self-Service Peer Benchmarking: With comprehensive data and anonymized insights across all platform users, customers now have direct access to reports on the portal, which enable them to easily benchmark their DevSecOps program results against others in their industry. Tapping into many years of data and learning, customers can see how their program metrics stack up and establish plans to address their risk.
- Software Bill of Materials (SBOM): Security teams can now generate and export SBOMs on demand with an integrated representational state transfer (REST) API. This returns data for a specific application in CycloneDX SBOM format—a standard designed for use in application security contexts and supply chain component analysis. Additionally, data from the API can be mined and transformed outside of the Veracode Platform.
- Intelligent Remediation: The Continuous Software Security Platform will leverage technology acquired from Jaroona to detect and remediate software vulnerabilities through machine learning. Jaroona, which was recognized by Gartner Research as a “Cool Vendor” in 2021, outperforms traditional approaches by 7x to 10x in terms of accuracy, false negatives, and false positive rates, and reduces the burden on technical resources.
According to Tabrez Naqvi, Director of Information Security and Risk at Cox Automotive, “The security of our products and services is very important to us, and Veracode helps us ensure that we never lose our customers' trust and confidence."
For more information on the Veracode Continuous Software Security Platform visit https://www.veracode.com/platform.
¹Gartner, Inc. ”Predicts 2022: Consolidated Security Platforms Are the Future” by Charlie Winckless, Joerg Fritsch, Peter Firstbrook, Neil MacDonald, Brian Lowans, 1 December 2021
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005671/en/
Contact information
For more information, please contact:
Katy Gwilliam
kgwilliam@veracode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
